A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this clinical research study is to learn whether Saxagliptin can improve the body's ability to make its own insulin and lower blood sugar in people with type 2 diabetes

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Metformin; Saxagliptin

Criteria

Inclusion Criteria:

• Type 2 diabetes mellitus

• Drug naive

• Hemoglobin A1c (HbA1c) ≥6.0% and ≤8.0%

• Fasting C-peptide ≥1.0 ng/mL

• Body mass index ≤40 kg/m²

Exclusion Criteria:

• Recent cardiac or cerebrovascular event

• Elevated serum creatinine